文献速递冠心病瓣膜病与结构性心脏病

氯沙坦对心肌梗死后二尖瓣改变的影响

Effect of Losartan on Mitral Valve Changes After Myocardial Infarction.
PubMed 文献 · J Am Coll Cardiol · 2017-01-01

在心肌梗死绵羊模型中,使用氯沙坦抑制TGF-β可显著减轻二尖瓣叶增厚、纤维化及内皮间质转化,且不消除适应性瓣叶生长,同时不显著改变动脉压。

要点

  • 氯沙坦减少梗死后二尖瓣叶厚度(0.9±0.2 mm vs 1.6±0.2 mm,p<0.05)。
  • 氯沙坦降低α-SMA阳性内皮细胞比例(27.2±12.0% vs 51.6±11.7%,p<0.05)。
  • 氯沙坦未消除瓣叶面积适应性增加(约17%)。

核心结论

  • 心肌梗死后二尖瓣叶的促纤维化改变可通过氯沙坦调控,且不消除适应性生长。

研究设计与样本

  • 研究评估17只绵羊,6只假手术对照,11只心尖部心肌梗死伴乳头肌牵拉但未产生二尖瓣反流;其中6只每日氯沙坦治疗,5只未治疗,均使用柔性心外膜网限制左室重构。

主要发现

  • 氯沙坦治疗组与未治疗限制组左室扩张和牵拉程度相当。
  • 氯沙坦显著降低瓣叶厚度(0.9±0.2 mm vs 1.6±0.2 mm,p<0.05;假手术组0.4±0.1 mm)。
  • 氯沙坦降低TGF-β及下游磷酸化ERK和内皮间质转化(α-SMA阳性内皮细胞27.2±12.0% vs 51.6±11.7%,p<0.05;假手术组7.2±3.5%)。
  • 氯沙坦减少细胞增殖、胶原沉积、内皮细胞活化(VCAM-1表达)、新生血管形成及CD45阳性细胞。
  • 限制组和氯沙坦治疗组瓣叶面积增加程度相当(17%)。

临床怎么用

  • 氯沙坦可能作为减轻缺血性二尖瓣反流中瓣叶纤维化的潜在治疗策略,但需进一步临床研究验证。

局限性

  • 研究为动物实验,样本量较小(17只绵羊),结果需在人体中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: After myocardial infarction (MI), mitral valve (MV) tethering stimulates adaptive leaflet growth, but counterproductive leaflet thickening and fibrosis augment mitral regurgitation (MR), doubling heart failure and mortality. MV fibrosis post-MI is associated with excessive endothelial-to-mesenchymal transition (EMT), driven by transforming growth factor (TGF)-β overexpression. In vitro, losartan-mediated TGF-β inhibition reduces EMT of MV endothelial cells. OBJECTIVES: This study tested the hypothesis that profibrotic MV changes post-MI are therapeutically accessible, specifically by losartan-mediated TGF-β inhibition. METHODS: The study assessed 17 sheep, including 6 sham-operated control animals and 11 with apical MI and papillary muscle retraction short of producing MR; 6 of the 11 were treated with daily losartan, and 5 were untreated, with flexible epicardial mesh comparably limiting left ventricular (LV) remodeling. LV volumes, tethering, and MV area were quantified by using three-dimensional echocardiography at baseline and at 60 ± 6 days, and excised leaflets were analyzed by histopathology and flow cytometry. RESULTS: Post-MI LV dilation and tethering were comparable in the losartan-treated and untreated LV constraint sheep. Telemetered sensors (n = 6) showed no significant losartan-induced changes in arterial pressure. Losartan strongly reduced leaflet thickness (0.9 ± 0.2 mm vs. 1.6 ± 0.2 mm; p < 0.05; 0.4 ± 0.1 mm sham animals), TGF-β, and downstream phosphorylated extracellular-signal-regulated kinase and EMT (27.2 ± 12.0% vs. 51.6 ± 11.7% α-smooth muscle actin-positive endothelial cells, p < 0.05; 7.2 ± 3.5% sham animals), cellular proliferation, collagen deposition, endothelial cell activation (vascular cell adhesion molecule-1 expression), neovascularization, and cells positive for cluster of differentiation (CD) 45, a hematopoietic marker associated with post-MI valve fibrosis. Leaflet area increased comparably (17%) in constrained and losartan-treated sheep. CONCLUSIONS: Profibrotic changes of tethered MV leaflets post-MI can be modulated by losartan without eliminating adaptive growth. Understanding the cellular and molecular mechanisms could provide new opportunities to reduce ischemic MR.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Bartko PE, Dal-Bianco JP, Guerrero JL, et al. Effect of Losartan on Mitral Valve Changes After Myocardial Infarction. J Am Coll Cardiol. 2017. PMID: 28859786. doi:10.1016/j.jacc.2017.07.734

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。